Parker & Waichman and Douglas & London File First Nationwide Class Action
Lawsuit Against Eli Lilly and Company on Behalf of all Persons Residing in t
he
United States Who Used Zyprexa
Parker & Waichman and Douglas & London Have Received Over Two Thousand Zypre
xa
Case Inquiries
PRNewswire -

04/19/04 - Parker & Waichman, LLP (www.yourlawyer.com) and Douglas & London 
LLP
announce the filing of the first nationwide class action lawsuit against Eli
Lilly and Company (NYSE: LLY - News) on behalf of all persons residing in th
e
United States who used Zyprexa. The lawsuit was filed on April 16, 2004 in t
he
United States District Court for the Eastern District of New York. Zyprexa i
s
currently the most popular atypical antipsychotic medication and is Eli Lill
y
and Company's best-selling pharmaceutical. Zyprexa has been linked to seriou
s
side effects including diabetes, hyperglycemia and pancreatitis. For informa
tion
on Zyprexa side effects and this class action lawsuit please visit
www.zyprexa-side-effects.com.

The class action lawsuit seeks relief for Zyprexa patients who have already 
been
diagnosed with side effects as well as compensation for medical testing for 
all
patients who have used Zyprexa in the United States. Three plaintiffs who ha
ve
been diagnosed with serious injuries have been named in the lawsuit. All of 
the
plaintiffs developed diabetes after taking Zyprexa and one plaintiff develop
ed
pancreatitis. Parker & Waichman has received over two thousand Zyprexa inqui
ries
from individuals claiming they have been injured.

Last year, the FDA requested that Eli Lilly and Company update its product
labeling for Zyprexa to include a warning about hyperglycemia and diabetes.
Additionally, the British Medical Control Agency and the Japanese Health and
Welfare Ministry have both warned about the risk of diabetes in patients who
 are
prescribed Zyprexa. In 2002, a study at Duke university showed a connection
between Zyprexa and diabetes. This study documented nearly 300 cases of diab
etes
in people using Zyprexa.

Zyprexa was approved for the treatment of schizophrenia in 1996 and for the
treatment of bipolar mania in 2000. It is part of a new generation of
antipsychotics known as atypicals, which include Seroquel, Risperdal, Abilif
y,
Clozaril, and Geodon. Ironically, the primary advantage of the newer atypica
l
antipsychotic medications was supposed to be a lower incidence of side effec
ts
than the conventional antipsychotics introduced in the 1950s (Haldol, Thoraz
ine,
Prolixin, Navane, Stelazine, Trilafon, and Mellaril). More information on
Zyprexa side effects is available at www.zyprexa-side-effects.com. Current a
nd
former Zyprexa users can visit this site to request a free legal evaluation.
 For
more information on Parker & Waichman, LLP please visit
http://www.yourlawyer.com or call 1-800-LAW-INFO.

Contact:

David Krangle, Esq.
Parker & Waichman, LLP
1-800-LAW-INFO (1-800-529-4636)
http://www.yourlawyer.com
dkrangle@yourlawyer.com

<< previous page

Report this post to a moderator

[  Post Follow-up to this message ]